Moderna's mRNA flu vaccine approved — does it outperform the standard shot?

Moderna's newly approved mRNA flu vaccine could allow manufacturers to respond more rapidly to changing influenza strains than traditional seasonal shots. Scientists say the mRNA platform's flexibility is its main advantage over conventional egg-based vaccine production. Research into whether the new vaccine is more effective than standard seasonal flu shots is ongoing.